The effect of bepridil, verapamil, and quinidine in the prevention of ventricular tachycardia induced by programmed electrical stimulation in the digitalized dog.
Bepridil, a new antianginal agent, has calcium channel-blocking activity and antiarrhythmic properties. To test the efficacy of bepridil as an antidysrhythmic agent, we looked at its effect on the induction of ventricular tachycardia (VT) in dogs, utilizing programmed electrical stimulation (PES). Incremental doses of bepridil up to 20 mg/kg were given to five nondigitalized dogs and verapamil up to 20 mg, and PES was performed at each dose. Both drugs were not found to facilitate arrhythmia induction. Seventeen dogs were chronically digitalized and following digitalization, VT could be induced in all animals by PES. Six dogs were given bepridil and PES was reperformed at each dose. An average of 1.8 mg/kg was found to protect against induction of VT. Five dogs received verapamil and none was protected (all had VT induced), while five of six dogs given quinidine were protected at an average dose of 15.4 mg/kg. Bepridil produced a significant decrease in heart rate. A significant correlation was found at the effective antiarrhythmic dose of bepridil between percentage change in the effective refractory period for the first extrastimulus (ERP S2) and QTc (r = 0.96), suggesting that a parallel and homogeneous prolongation in repolarization and refractoriness is essential for the antiarrhythmic effect of bepridil. Bepridil is thus an effective antiarrhythmic agent that affords protection against induction of VT, and this action is similar to the conventional class I antiarrhythmic agent, quinidine, while lacking in another calcium channel blocker, verapamil.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D015764:Bepridil; D004285:Dogs; D004558:Electric Stimulation / Q000379:methods*; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D008297:Male; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use; D011802:Quinidine / Q000008:administration & dosage / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D011759:Pyrrolidines; D015764:Bepridil; D014700:Verapamil; D011802:Quinidine